Carrier Ligand Effects in Platinum Resistant Cell Lines

  • Stephen G. Chaney
  • Gregory R. Gibbons
  • Wendelyn Schmidt
  • Jimmy D. Page

Abstract

Cisplatin resistance is a major clinical problem. Studies performed in a number of laboratories have shown that cisplatin resistance is multifactorial and varies significantly from one cell line to another. Our laboratory has focused on the carrier ligand effects on resistance, particularly those effects involving the diaminocyclohexane (dach) carrier ligand. The dach carrier ligand is of both historical and clinical interest. In 1977 Burchenal and coworkers first showed that platinum complexes with the dach ligand were effective in L1210 and P388 cell lines which were resistant to cisplatin (1,2). Similar findings have subsequently been reported in a number of cisplatin-resistant human cell lines (3–5). While relatively little is known about the mechanism of these carrier ligand effects, one dach-Pt compound, tetrachloro(trans-d) 1,2-diaminocyclohexaneplatinum(IV) (also known as tetraplatin or ormaplatin), is currently in phase I clinical trials. We initiated studies into the mechanism of these dach ligand effects because we felt that this type of information might allow one to predict the clinical situations where ormaplatin and other dach-Pt complexes would be most effective. Such information might also help in the design and/or selection of more effective second generation platinum complexes, and might allow one to design assays which would predict the likely efficacy of these complexes in treating cisplatin-resistant tumors. Finally, we felt information on the mechanism of carrier ligand effects should contribute to our overall understanding of the resistance phenomenon.

Keywords

Platinum Glutathione Adduct Toxicology Malonate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.H. Burchenal, K. Kalaher, T. O’Toole and J. Chisolm, Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia, Cancer Res., 37:3455–3457 (1977).PubMedGoogle Scholar
  2. 2.
    J.H. Burchenal, K. Kalaher, K. Dew and L. Lokys, Rationale for the development of platinum analogs, Cancer Treatment Rep., 63:1493–1497 (1979).Google Scholar
  3. 3.
    P.A. Andrews, M.P. Murphy and S.B. Howell, Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells, Eur. J. Cancer Clin. Oncol., 25:619–625 (1989).PubMedCrossRefGoogle Scholar
  4. 4.
    B.C. Behrens, T.C. Hamilton, H. Masuda, K.R. Grotzinger, J. Whang-Peng, K.G. Louie, T. Knutsen, W.M. McKay, R.C. Young, and R.F. Ozols, Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues, Cancer Res., 47:414–418 (1987).PubMedGoogle Scholar
  5. 5.
    C.A. Hills, L.R. Kelland, G. Abel, J. Siracky, A.P. Wilson and K.R. Harrap, Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes, Br. J. Cancer, 59:527–534 (1989).PubMedCrossRefGoogle Scholar
  6. 6.
    A. Eastman and E. Bresnick, Studies on the resistance of a murine leukemia L1210 cell line to cis-diamminedichloroplatinum(II), Biochem. Pharmacol., 30:2723–2725.Google Scholar
  7. 7.
    A. Eastman and S. Illenye, Murine leukemia L1210 cell lines with different patterns of resistance to platinum coordination complexes, Cancer Treatment. Rep., 68:1189–1190 (1984).Google Scholar
  8. 8.
    Y. Lu, J. Han and K.J. Scanlon, Biological and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid, J. Biol. Chem., 263:4891–4894 (1988).PubMedGoogle Scholar
  9. 9.
    K.J. Scanlon, M. Kashani-Sabet and L.C. Sowers, Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine, Cancer Commun., 1:269–275 (1989).PubMedGoogle Scholar
  10. 10.
    Y. Kidani, M. Noji, S. Tsukagoshi and T. Tashiro, Antitumor activity of water-soluble platinum(II) complexes of 1,2-cyclohexanediamine isomers, Gann, 69:263–265 (1978).PubMedGoogle Scholar
  11. 11.
    M. Noji, N. Okamoto, Y. Kidani and T. Tashiro, Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl) cyclohexylamine isomers against leukemia P388, J. Med. Chem., 24:508–515 (1981).PubMedCrossRefGoogle Scholar
  12. 12.
    J.D. Page, I. Husain, A. Sancar and S.G. Chaney, Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality, Biochemistry, 29:1016–1024 (1990).PubMedCrossRefGoogle Scholar
  13. 13.
    G.R. Gibbons, J.D. Page, S.K. Mauldin, I. Husain and S.G. Chaney, Role of carrier ligand in platinum resistance in L1210 cells, Cancer Res., 50:6497–6501 (1990).PubMedGoogle Scholar
  14. 14.
    W.K. Anderson, D.A. Quagliato, R.D. Haugwitz, V.L. Narayan and M.K. Wolpert-DeFillipes, Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(II) stereoisomers of 1,2-diaminocyclohexane, Cancer Treatment Rep., 70:997–1002 (1986).Google Scholar
  15. 15.
    C.J.L. Lock and P. Pilon, Tris[cis-dichloro(1,2-diaminocyclohexane) platinum(II)] hydrate and cis-dibromo-(1,2-diaminocyclohexane) platinum(II) isomers with d(GpG), Acta Crystallogr., B37:45–49 (1981).Google Scholar
  16. 16.
    K. Inagaki and Y. Kidani, Differences in binding of (1,2-diaminocyclohexane)platinum(II) isomers with d(GpG), Inorg. Chem., 25:1–4 (1986).CrossRefGoogle Scholar
  17. 17.
    M.M. Jennerwein, A. Eastman and A. Khokher, Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes, Chem.-Biol. Interact., 70:39–49 (1989).PubMedCrossRefGoogle Scholar
  18. 18.
    D.P. Bancroft, C.A. Lepre and S.J. Lippard, 195Pt NMR kinetic and mechanistic studies of cis-and trans-diamminedichloroplatinum(II) binding to DNA, J. Am. Chem. Soc., 112:6860–6871 (1990).CrossRefGoogle Scholar
  19. 19.
    K.H. Miller, S.L. McCarthy and M. Krauss, Binding of cis-(1,2-diaminocyclohexane)platinum(II) and its derivatives to duplex DNA, J. Med. Chem., 33:1043–1046 (1990).PubMedCrossRefGoogle Scholar
  20. 20.
    A. Eastman, Crosslinking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem. Biol. Interact., 61:241–248 (1987).PubMedCrossRefGoogle Scholar
  21. 21.
    G. Gibbons, S. Wyrick and S.G. Chaney, Rapid reduction of tetrachloro(d,1-trans)1,2-diaminocylcohexaneplatinum(IV) (tetraplatin) in RPMI-1640 tissue culture medium, Cancer Res., 49:1402–1407 (1989).PubMedGoogle Scholar
  22. 22.
    S.K. Mauldin, I. Husain, A. Sancar and S.G. Chaney, Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line, Cancer Res., 46:2876–2882 (1986).PubMedGoogle Scholar
  23. 23.
    K.J. Scanlon, E. Newman, Y. Lu and D.G. Priest, Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells, Proc. Natl. Acad. Sci. (USA), 23:8923–8925 (1986).CrossRefGoogle Scholar
  24. 24.
    S.C. Mann, P.A. Andrews and S.B. Howell, Short term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells, Cancer Chemotherap. Pharmacol., 25:236–240 (1990).CrossRefGoogle Scholar
  25. 25.
    A.J. Kraker and C.W. Moore, Accumulation of cis-diamminedichloroplatinum(II) and platinum analogs by platinum-resistant murine leukemia cells in vitro, Cancer Res., 48:9–13 (1988).PubMedGoogle Scholar
  26. 26.
    V.M. Richon, N. Schulte and A. Eastman, Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells, Cancer Res., 47:2056–2061 (1987).PubMedGoogle Scholar
  27. 27.
    A. Eastman and N. Schulte, Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II), Biochemistry, 27:4730–4734 (1988).PubMedCrossRefGoogle Scholar
  28. 28.
    M.M. Jennerwein, A. Eastman and A.R. Khokhar, The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation, Mutation Res., 254:89–96 (1991).PubMedCrossRefGoogle Scholar
  29. 29.
    W.K. Kaufmann and J.E. Cleaver, Mechanisms of inhibition of DNA replication by ultraviolet light in normal human and Xeroderma pigmentosum fibroblasts, J. Mol. Biol., 149:171–187 (1981).PubMedCrossRefGoogle Scholar
  30. 30.
    M. Cordeiro-Stone, J. Boyer, B.A. Smith and W.K. Kaufmann, Xeroderma pigmentosum variant and normal fibroblasts show the same response to inhibition of DNA replication by benzo[a]pyrene-diol-epoxide-I, Carcinogenesis, 7:1783–1786 (1986).PubMedCrossRefGoogle Scholar
  31. 31.
    J.C. Boyer, W.K. Kaufmann, B.P. Brylawski and M. Cordeiro-Stone, Defective postreplication repair in Xeroderma pigmentosum variant fibroblasts, Cancer Res., 50:2593–2598 (1990).PubMedGoogle Scholar
  32. 32.
    A.L. Pinto and S.J. Lippard, Sequence-dependent termination of in vitro DNA synthesis by cis-and trans-diamminedichloroplatinum(II), Proc. Natl. Acad. Sci. (USA), 82:4616–4619.Google Scholar
  33. 33.
    G. Villani, U. Hübscher and J.L. Butour, Sites of termination of in vitro DNA synthesis on cis-diamminedichloroplatinum(II) treated single-stranded DNA: a comparison between E. coli DNA polymerase I and eucaryotic DNA polymerase a, Nucleic. Acid Res., 16:4407–4418 (1988).PubMedCrossRefGoogle Scholar
  34. 34.
    J.S. Hoffmann, N.P. Johnson and G. Villani, Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum(II) to bifunctional lesions, J. Biol. Chem., 264:15130–15135 (1989).PubMedGoogle Scholar
  35. 35.
    W.J. Heiger-Bernays, J.M. Essigmann and S.J. Lippard, Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication, Biochemistry, Vol. 29:8461–8466 (1990).PubMedCrossRefGoogle Scholar
  36. 36.
    D. Burnouf, C. Gauthier, J.C. Chottard and R.P.P. Fuchs, Single d(AG)/cis-diamminedichloroplatinum(II) adduct-induced mutagenesis in Escherichia coli, Proc. Natl. Acad. Sci. (USA), 87:6087–6091 (1990).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Stephen G. Chaney
    • 1
  • Gregory R. Gibbons
    • 1
  • Wendelyn Schmidt
    • 1
  • Jimmy D. Page
    • 1
  1. 1.Department of Biochemistry and Biophysics and Curriculum in ToxicologyUniversity of North CarolinaChapel HillUSA

Personalised recommendations